Fluorescein

Azura Ophthalmics Announces Positive Results from Phase 2 Clinical Trial of AZR-MD-001 in Patients with Contact Lens Discomfort

Retrieved on: 
Monday, December 18, 2023
Biotechnology, Health, Pharmaceutical, Optical, Clinical Trials, Contact lens, CLD, Meibomian gland dysfunction, Safety, Gland, Lens, Eyelid, Irritation, AZR, Dry, Patient, FDA, Ophthalmic, Fluorescein, Contact, MGD, MGS, Pain, Quality of life, Telescopic sight, Azura

This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.

Key Points: 
  • This is the second positive Phase 2 study of AZR-MD-001 to demonstrate statistically significant improvements across multiple sign and symptom endpoints in patients with MGD.
  • “MGD is the root cause of many downstream ocular surface conditions that impact quality of life and vision for patients, including Contact Lens Discomfort.
  • This leads to several downstream ocular surface symptoms including dryness, pain, irritation, reduced quality of vision, and Contact Lens Discomfort.
  • “MGD is one of the causes of Contact Lens Discomfort, and many patients give up on wearing contact lenses altogether due to the irritation they experience.

Global Dry Eye Treatment Devices Market Report 2022: An Upsurge in The Number of Eye Care Facilities Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Health, Optical, Patient, Stinger, Prevalence, Fluorescein, Thyroid, Ophthalmology, Visual impairment, Tears, Hyperaemia, Rheumatoid arthritis, Lupus, DED, Dry eye syndrome, Tearing, Dry, Conditional sentence, Maintenance, Green, Eye, Grit, Wound healing, Diabetes, Schirmer, Rose bengal, Infection, Blepharitis, Drainage, Sjögren syndrome, Cosmetics

The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report by Technology, End-user, Regional Outlook and Forecast, 2022-2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Dry Eye Treatment Devices Market size is expected to reach $348.8 million by 2028, rising at a market growth of 7.4% CAGR during the forecast period.
  • Several medical remedies and methods are either on the market or being researched for the management of DED.
  • The number of people with dry eyes has grown recently for a variety of causes, leading to an increase in eye care facilities.

Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells

Retrieved on: 
Tuesday, May 3, 2022
Child, Statistics, COVID-19, Hope, Drug development, Hematological Cancer Research Investment and Education Act, IND, Seattle Children's, Health, GLOBE, Clinical Cancer Research, Company, Neoplasm, Enlightenment, Osteosarcoma, Seattle, Safety, Food, CAR, Adolescence, OS, U.S. News & World Report, Patient, Umoja, Foundation, Partnership, Clinical trial, FDA, Cancer, Hospital, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, UB, PMID, Social disruption, Ageing, Prognosis, Neuroscience, Fluorescein, News, Infection, Survival rate, Purdue University, Research, Sarcoma, Nursing care plan, Pharmaceutical industry, Medical imaging, Vaccine

We are excited to receive IND clearance of our first TumorTag product candidate UB-TT170, said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma.

Key Points: 
  • We are excited to receive IND clearance of our first TumorTag product candidate UB-TT170, said Andy Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma.
  • The ability to target solid tumors with CAR T technology remains a large barrier for patients with cancer.
  • The ENLIGHTen trial ( NCT05312411 ) is an open-label Phase 1 feasibility and safety study of fluorescein-specific CAR T cells in combination with folate-fluorescein (UB-TT170) for patients with refractory/recurrent osteogenic sarcoma.
  • The primary endpoint is safety (adverse events tracking) with secondary endpoints focused on the ability to manufacture anti-fluorescein CAR T cells.

Vernier Software & Technology Introduces Five New Go Direct® Products for College-Level Science

Retrieved on: 
Tuesday, February 1, 2022
Fluorescence, CEO, Vernier Software & Technology, Aspirin, DNA, Next Generation Science Standards, Learning, USB, Mathematics, STEM, Engineering, Technology, Fluorescein, Chlorophyll, NADH, NGSS, Student, Chemistry, Beer–Lambert law, Physics, Science, Education, Protein, Biology, Management, Vernier

BEAVERTON, Ore., Feb. 1, 2022 /PRNewswire/ --Vernier Software & Technology recently launched five new Go Direct products for college-level science.

Key Points: 
  • BEAVERTON, Ore., Feb. 1, 2022 /PRNewswire/ --Vernier Software & Technology recently launched five new Go Direct products for college-level science.
  • "In college-level science coursework, it's critical that educators and students have accurate data," said John Wheeler, CEO of Vernier Software & Technology.
  • Vernier Software & Technology has led the innovation of educational, scientific data-collection technology for over 40years.
  • The company is committed to teachers and to developing creative ways to teach and learn science, technology, engineering, and mathematics (STEM) using hands-on science.

Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program

Retrieved on: 
Tuesday, February 16, 2021
Angiology, Aromatic compounds, Chemical compounds, Medical specialties, Medical terminology, Neovascularization, Bascom Palmer Eye Institute, Angiogenesis, Fluorescein

delivered a presentation entitled, Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Bascom Palmer Eye Institute on February 12 & 13, 2021.

Key Points: 
  • delivered a presentation entitled, Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Bascom Palmer Eye Institute on February 12 & 13, 2021.
  • This compartmentalized delivery to affected posterior tissues may minimize treatment related adverse events, such as vitreous floaters and corneal and anterior segment exposure.
  • Preclinical results from Clearside and independent investigators have shown pharmacodynamic effects with reduced growth of experimental neovascularization and decreased fluorescein leakage.
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Fluorescein Angiography Market Size Worth $617.4 Million By 2027: Grand View Research, Inc.

Retrieved on: 
Wednesday, August 26, 2020
Aromatic compounds, Optical imaging, Medicine, Clinical medicine, Projectional radiography, Fluorescein angiography, Fluorescein, Angiography

However, the growing preference for safer and faster alternatives such as OCT and fundus autofluorescence is anticipated to impede market growth during the forecast period.

Key Points: 
  • However, the growing preference for safer and faster alternatives such as OCT and fundus autofluorescence is anticipated to impede market growth during the forecast period.
  • Despite preference of its alternatives, fluorescein angiography is often used as confirmatory test for a wide range of ophthalmic conditions.
  • In addition, the demand for tradition fluorescein angiography systems is still high in developing countries.
  • Grand View Research has segmented the global fluorescein angiography market based on product, technology, application, and region:

Fluorescein Angiography Market Size Worth $617.4 Million By 2027: Grand View Research, Inc.

Retrieved on: 
Wednesday, August 26, 2020
Aromatic compounds, Optical imaging, Medicine, Clinical medicine, Projectional radiography, Fluorescein angiography, Fluorescein, Angiography

However, the growing preference for safer and faster alternatives such as OCT and fundus autofluorescence is anticipated to impede market growth during the forecast period.

Key Points: 
  • However, the growing preference for safer and faster alternatives such as OCT and fundus autofluorescence is anticipated to impede market growth during the forecast period.
  • Despite preference of its alternatives, fluorescein angiography is often used as confirmatory test for a wide range of ophthalmic conditions.
  • In addition, the demand for tradition fluorescein angiography systems is still high in developing countries.
  • Grand View Research has segmented the global fluorescein angiography market based on product, technology, application, and region: